BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee AH, Sun L, Mochizuki AY, Reynoso JG, Orpilla J, Chow F, Kienzler JC, Everson RG, Nathanson DA, Bensinger SJ, Liau LM, Cloughesy T, Hugo W, Prins RM. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nat Commun 2021;12:6938. [PMID: 34836966 DOI: 10.1038/s41467-021-26940-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 16.5] [Reference Citation Analysis]
Number Citing Articles
1 Piyadasa H, Angelo M, Bendall SC. Spatial proteomics of tumor microenvironments reveal why location matters. Nat Immunol 2023. [PMID: 36959293 DOI: 10.1038/s41590-023-01471-8] [Reference Citation Analysis]
2 Choi Y, Lichterman JN, Coughlin LA, Poulides N, Li W, Del Valle P, Palmer SN, Gan S, Kim J, Zhan X, Gao Y, Evers BM, Hooper LV, Pasare C, Koh AY. Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal antitumor immunity. Sci Immunol 2023;8:eabo2003. [PMID: 36867675 DOI: 10.1126/sciimmunol.abo2003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 White K, Connor K, Meylan M, Bougoüin A, Salvucci M, Bielle F, O'Farrell AC, Sweeney K, Weng L, Bergers G, Dicker P, Ashley DM, Lipp ES, Low JT, Zhao J, Wen P, Prins R, Verreault M, Idbaih A, Biswas A, Prehn JHM, Lambrechts D, Arijs I, Lodi F, Dilcan G, Lamfers M, Leenstra S, Fabro F, Ntafoulis I, Kros JM, Cryan J, Brett F, Quissac E, Beausang A, MacNally S, O'Halloran P, Clerkin J, Bacon O, Kremer A, Chi Yen RT, Varn FS, Verhaak RGW, Sautès-Fridman C, Fridman WH, Byrne AT. Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy. Ann Oncol 2023;34:300-14. [PMID: 36494005 DOI: 10.1016/j.annonc.2022.11.008] [Reference Citation Analysis]
4 Chakravarti AR, Groer CE, Gong H, Yudistyra V, Forrest ML, Berkland CJ. Design of a Tumor Binding GMCSF as Intratumoral Immunotherapy of Solid Tumors. Mol Pharm 2023. [PMID: 36825806 DOI: 10.1021/acs.molpharmaceut.2c00897] [Reference Citation Analysis]
5 Kilian M, Sheinin R, Tan CL, Friedrich M, Krämer C, Kaminitz A, Sanghvi K, Lindner K, Chih YC, Cichon F, Richter B, Jung S, Jähne K, Ratliff M, Prins RM, Etminan N, von Deimling A, Wick W, Madi A, Bunse L, Platten M. MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. Cancer Cell 2023;41:235-251.e9. [PMID: 36638785 DOI: 10.1016/j.ccell.2022.12.007] [Reference Citation Analysis]
6 Li J, Zhou J, Huang H, Jiang J, Zhang T, Ni C. Mature dendritic cells enriched in immunoregulatory molecules (mregDCs): A novel population in the tumour microenvironment and immunotherapy target. Clin Transl Med 2023;13:e1199. [PMID: 36808888 DOI: 10.1002/ctm2.1199] [Reference Citation Analysis]
7 Morimoto T, Nakazawa T, Maeoka R, Nakagawa I, Tsujimura T, Matsuda R. Natural Killer Cell-Based Immunotherapy against Glioblastoma. Int J Mol Sci 2023;24. [PMID: 36768432 DOI: 10.3390/ijms24032111] [Reference Citation Analysis]
8 Kalluri AL, Shah PP, Lim M. The Tumor Immune Microenvironment in Primary CNS Neoplasms: A Review of Current Knowledge and Therapeutic Approaches. Int J Mol Sci 2023;24. [PMID: 36768342 DOI: 10.3390/ijms24032020] [Reference Citation Analysis]
9 Arrieta VA, Dmello C, McGrail DJ, Brat DJ, Lee-Chang C, Heimberger AB, Chand D, Stupp R, Sonabend AM. Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. J Clin Invest 2023;133. [PMID: 36647828 DOI: 10.1172/JCI163447] [Reference Citation Analysis]
10 Kazakova A, Sudarskikh T, Kovalev O, Kzhyshkowska J, Larionova I. Interaction of tumor‑associated macrophages with stromal and immune components in solid tumors: Research progress (Review). Int J Oncol 2023;62:32. [PMID: 36660926 DOI: 10.3892/ijo.2023.5480] [Reference Citation Analysis]
11 Yang Y, Fu X, Liu R, Yan L, Yang Y. Exploring the prognostic value of HK3 and its association with immune infiltration in glioblastoma multiforme. Front Genet 2022;13:1033572. [PMID: 36712881 DOI: 10.3389/fgene.2022.1033572] [Reference Citation Analysis]
12 Hou D, Castro B, Dapash M, Zolp A, Katz J, Arrieta V, Biermann J, Melms J, Kueckelhaus J, Benotmane J, Youngblood M, Rashidi A, Billingham L, Dmello C, Vazquez-Cervantes G, Lopez-Rosas A, Han Y, Patel R, Chia TY, Sun L, Prins R, Izar B, Heiland DH, Zhang P, Sonabend A, Miska J, Lesniak M, Zhao J, Lee-Chang C. B-cells Drive Response to PD-1 Blockade in Glioblastoma Upon Neutralization of TGFβ-mediated Immunosuppression. Res Sq 2023:rs. [PMID: 36711497 DOI: 10.21203/rs.3.rs-2399170/v1] [Reference Citation Analysis]
13 Frederico SC, Darling C, Bielanin JP, Dubinsky AC, Zhang X, Hadjipanayis CG, Kohanbash G. Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier. Front Immunol 2023;14:1057567. [PMID: 36875096 DOI: 10.3389/fimmu.2023.1057567] [Reference Citation Analysis]
14 Di Giacomo AM, Mair MJ, Ceccarelli M, Anichini A, Ibrahim R, Weller M, Lahn M, Eggermont AMM, Fox B, Maio M. Immunotherapy for brain metastases and primary brain tumors. Eur J Cancer 2023;179:113-20. [PMID: 36521332 DOI: 10.1016/j.ejca.2022.11.012] [Reference Citation Analysis]
15 Xuan Z, Fang L, Zhang G, Zhang X, Jiang J, Wang K, Huang P. The Heterogeneity of Tumour-Associated Macrophages Contributes to the Recurrence and Outcomes of Glioblastoma Patients. J Mol Neurosci 2023;73:1-14. [PMID: 36542317 DOI: 10.1007/s12031-022-02081-z] [Reference Citation Analysis]
16 Massenzio F, Cambiaghi M, Marchiotto F, Boriero D, Limatola C, D'Alessandro G, Buffelli M. In vivo morphological alterations of TAMs during KCa3.1 inhibition-by using in vivo two-photon time-lapse technology. Front Cell Neurosci 2022;16:1002487. [PMID: 36589283 DOI: 10.3389/fncel.2022.1002487] [Reference Citation Analysis]
17 Park JH, Kang I, Lee HK. The immune landscape of high-grade brain tumor after treatment with immune checkpoint blockade. Front Immunol 2022;13:1044544. [PMID: 36591276 DOI: 10.3389/fimmu.2022.1044544] [Reference Citation Analysis]
18 Zhao J, Dong Y, Zhang Y, Wang J, Wang Z. Biophysical heterogeneity of myeloid-derived microenvironment to regulate resistance to cancer immunotherapy. Adv Drug Deliv Rev 2022;191:114585. [PMID: 36273512 DOI: 10.1016/j.addr.2022.114585] [Reference Citation Analysis]
19 Wu Y, Zhang W, Zhao Y, Wang X, Guo G. Technology development trend of electrospray ionization mass spectrometry for single-cell proteomics. TrAC Trends in Analytical Chemistry 2022. [DOI: 10.1016/j.trac.2022.116913] [Reference Citation Analysis]
20 Prins RM, Everson RG. Commentary on "Dysfunctional dendritic cells limit antigen-specific T cell response in glioma". Neuro Oncol 2023;25:277-8. [PMID: 36445342 DOI: 10.1093/neuonc/noac256] [Reference Citation Analysis]
21 Zhou X, Chen B, Zhang Z, Huang Y, Li J, Wei Q, Cao D, Ai J. Crosstalk between Tumor-Associated Macrophages and MicroRNAs: A Key Role in Tumor Microenvironment. IJMS 2022;23:13258. [DOI: 10.3390/ijms232113258] [Reference Citation Analysis]
22 Mirzaei R, Yong VW. Microglia-T cell conversations in brain cancer progression. Trends Mol Med 2022:S1471-4914(22)00211-8. [PMID: 36075812 DOI: 10.1016/j.molmed.2022.08.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Vermare A, Guérin MV, Peranzoni E, Bercovici N. Dynamic CD8+ T Cell Cooperation with Macrophages and Monocytes for Successful Cancer Immunotherapy. Cancers 2022;14:3546. [DOI: 10.3390/cancers14143546] [Reference Citation Analysis]
24 Lin YJ, Wu CY, Wu JY, Lim M. The Role of Myeloid Cells in GBM Immunosuppression. Front Immunol 2022;13:887781. [PMID: 35711434 DOI: 10.3389/fimmu.2022.887781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Kreatsoulas D, Bolyard C, Wu BX, Cam H, Giglio P, Li Z. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence. J Hematol Oncol 2022;15:80. [PMID: 35690784 DOI: 10.1186/s13045-022-01298-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Chen F, Xie X, Chao M, Cao H, Wang L. The Potential Value of m6A RNA Methylation in the Development of Cancers Focus on Malignant Glioma. Front Immunol 2022;13:917153. [DOI: 10.3389/fimmu.2022.917153] [Reference Citation Analysis]
27 Bridges K, Miller-Jensen K. Mapping and Validation of scRNA-Seq-Derived Cell-Cell Communication Networks in the Tumor Microenvironment. Front Immunol 2022;13:885267. [PMID: 35572582 DOI: 10.3389/fimmu.2022.885267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Brown MC, Ashley DM, Khasraw M. Low tumor mutational burden and immunotherapy in gliomas. Trends Cancer 2022;8:345-6. [PMID: 35093301 DOI: 10.1016/j.trecan.2022.01.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Pang L, Khan F, Dunterman M, Chen P. Pharmacological targeting of the tumor–immune symbiosis in glioblastoma. Trends in Pharmacological Sciences 2022. [DOI: 10.1016/j.tips.2022.04.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Wang L, Cao H, Zhong Y, Ji P, Chen F. The Role of m6A Regulator-Mediated Methylation Modification and Tumor Microenvironment Infiltration in Glioblastoma Multiforme. Front Cell Dev Biol 2022;10:842835. [PMID: 35265626 DOI: 10.3389/fcell.2022.842835] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Andersen JK, Miletic H, Hossain JA. Tumor-Associated Macrophages in Gliomas—Basic Insights and Treatment Opportunities. Cancers 2022;14:1319. [DOI: 10.3390/cancers14051319] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
32 Crivii CB, Boșca AB, Melincovici CS, Constantin AM, Mărginean M, Dronca E, Suflețel R, Gonciar D, Bungărdean M, Șovrea A. Glioblastoma Microenvironment and Cellular Interactions. Cancers (Basel) 2022;14:1092. [PMID: 35205842 DOI: 10.3390/cancers14041092] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
33 Bartkowiak T, Lima SM, Hayes MJ, Mistry AM, Sinnaeve J, Leelatian N, Roe CE, Mobley BC, Weaver KD, Thompson RC, Chambless LB, Ihrie RA, Irish JM. Immune cell regulation in stem cell niche contacting glioblastomas.. [DOI: 10.1101/2022.02.16.480731] [Reference Citation Analysis]
34 Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z, Dai Z, Zhang X, Zhang L, Peng Y, Ye W, Zeng W, Liu Z, Cheng Q. Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer 2022;21:39. [PMID: 35135556 DOI: 10.1186/s12943-022-01513-z] [Cited by in Crossref: 50] [Cited by in F6Publishing: 58] [Article Influence: 50.0] [Reference Citation Analysis]
35 Liu W, Xia L, Xia Z, Chen L. Comprehensive Analysis of Innate Immunophenotyping Based on Immune Score Predicting Immune Alterations and Prognosis in Breast Cancer Patients. Genes 2022;13:88. [DOI: 10.3390/genes13010088] [Reference Citation Analysis]
36 Chen Q, Zhang L, Li L, Tan M, Liu W, Liu S, Xie Z, Zhang W, Wang Z, Cao Y, Shang T, Ran H. Cancer cell membrane-coated nanoparticles for bimodal imaging-guided photothermal therapy and docetaxel-enhanced immunotherapy against cancer. J Nanobiotechnology 2021;19:449. [PMID: 34952587 DOI: 10.1186/s12951-021-01202-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
37 Arrieta VA, Najem H, Petrosyan E, Lee-Chang C, Chen P, Sonabend AM, Heimberger AB. The Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia. Int J Mol Sci 2021;22:13382. [PMID: 34948178 DOI: 10.3390/ijms222413382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]